scholarly journals Nuclear Expression of Snail Is an Independent Negative Prognostic Factor in Human Breast Cancer

2013 ◽  
Vol 35 ◽  
pp. 337-344 ◽  
Author(s):  
S. Muenst ◽  
S. Däster ◽  
E. C. Obermann ◽  
R. A. Droeser ◽  
W. P. Weber ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Human Cancer ◽  
Lymph Node Status ◽  
Intrinsic Subtypes ◽  
Snail Expression ◽  
Mesenchymal Transition ◽  
Luminal B ◽  
Negative Prognostic Factor ◽  
Independent Negative Prognostic Factor

Background. Snail is a key regulator of epithelial-mesenchymal transition of tumor cells. Several studies have shown nuclear Snail expression to be a negative prognostic factor in human cancer, where it is generally associated with more aggressive tumor behavior and worse survival.Objectives and Methods. To further explore the role of Snail expression in breast cancer, we conducted a study on a tissue microarray, encompassing 1043 breast cancer cases.Results. A total of 265 (25.4%) breast cancers were positive for Snail. Snail expression was significantly associated with greater tumor size, higher tumor stage and grade, positive lymph node status, and hormone receptor negative status and was differently expressed in the intrinsic subtypes of breast cancer, being the highest in the basal-like subtype and the lowest in the luminal A subtype. In multivariate analysis, Snail proved to be an independent negative prognostic factor for OS. In the intrinsic subtypes, Snail expression was a negative prognostic factor for OS in the luminal B HER2−, the luminal B HER2+, and the basal-like subtype.Conclusions. This is the first study demonstrating that nuclear Snail expression is an independent negative predictor of prognosis in breast cancer, thus suggesting that it may represent a potential therapeutic target.

scholarly journals Src homology phosphotyrosyl phosphatase-2 expression is an independent negative prognostic factor in human breast cancer

2013 ◽  
Vol 63 (1) ◽  
pp. 74-82 ◽  
Author(s):  
Simone Muenst ◽  
Ellen C Obermann ◽  
Feng Gao ◽  
Daniel Oertli ◽  
Carsten T Viehl ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Negative Prognostic Factor ◽  
Src Homology ◽  
Independent Negative Prognostic Factor

scholarly journals Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences

2013 ◽  
Vol 8 (1) ◽  
pp. 119-128 ◽  
Author(s):  
Siker Kimbung ◽  
Anikó Kovács ◽  
Pär-Ola Bendahl ◽  
Per Malmström ◽  
Mårten Fernö ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Negative Prognostic Factor ◽  
Independent Negative Prognostic Factor

scholarly journals Circulating Tumor Cells Counting Act as a Potential Prognostic Factor in Cervical Cancer

2020 ◽  
Vol 19 ◽  
pp. 153303382095700 ◽  
Author(s):  
Kunpeng Du ◽  
Qian Huang ◽  
Junguo Bu ◽  
Jieling Zhou ◽  
Zijian Huang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Prognostic Factor ◽  
Progression Free Survival ◽  
Disease Stage ◽  
Histological Differentiation ◽  
Free Survival ◽  
Pathological Type ◽  
Negative Prognostic Factor ◽  
The Relationship ◽  
Independent Negative Prognostic Factor

Background: Circulating tumor cells (CTCs) hold huge potential for both clinical applications and basic research into the management of cancer, but the relationship between CTC count and cervical cancer prognosis remains unclear. Therefore, research on this topic is urgently required. Objective: This study investigated whether CTCs were detectable in patients with cervical cancer and whether CTC count was an indicator of prognosis. Methods: We enrolled 107 patients with pathologically confirmed cervical cancer. CTCs were detected after radiotherapy or concurrent cisplatin-containing chemotherapy in all patients. We evaluated all medical records and imaging data as well as follow-up information to calculate progression-free survival (PFS). PFS was defined as the time until first diagnosis of tumor progression or death. We also analyzed the relationship between CTC count and patient age, disease stage, histological differentiation, tumor size, and pathological type. Results: CTCs were identified in 86 of 107 patients (80%), and the CTC count ranged from 0 to 27 cells in 3.2 mL blood. The median progression-free survival (PFS) was 43.1 months. Patients in which CTCs were detected had a significantly shorter PFS than CTC-negative patients (P = 0.018). Multivariate analysis indicated that CTC count was an independent negative prognostic factor for survival. However, no correlation was observed between CTC count and patient age, disease stage, histological differentiation, tumor size, and pathological type. Conclusion: CTC count is an independent negative prognostic factor for cervical cancer.

scholarly journals EMMPRIN Is an Independent Negative Prognostic Factor for Patients with Astrocytic Glioma

PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e58069 ◽  
Author(s):  
Li Tian ◽  
Yang Zhang ◽  
Yu Chen ◽  
Min Cai ◽  
Hailong Dong ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Astrocytic Glioma ◽  
Negative Prognostic Factor ◽  
Independent Negative Prognostic Factor

scholarly journals Association between Lymph Node Status and Expression Levels of Androgen Receptor, miR-185, miR-205, and miR-21 in Breast Cancer Subtypes

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Tatiana S. Kalinina ◽  
Vladislav V. Kononchuk ◽  
Alisa K. Yakovleva ◽  
Efim Y. Alekseenok ◽  
Sergey V. Sidorov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Androgen Receptor ◽  
Expression Profiles ◽  
Lymph Node Status ◽  
Her2 Positive ◽  
Expression Levels ◽  
Cancer Subtypes ◽  
Luminal B ◽  
Cancer Spread

Breast cancer is the most commonly diagnosed cancer among women. Difficulties in treating breast cancer are associated with the occurrence of metastases at early stages of disease, leading to its further progression. Recent studies have shown that changes in androgen receptor (AR) and microRNAs’ expressions are associated with mammary gland carcinogenesis, in particular, with the formation of metastases. Thus, to identify novel metastatic markers, we evaluated the expression levels of AR; miR-185 and miR-205, both of which have been confirmed to target AR; and miR-21, transcription of which is regulated by AR, in breast cancer samples (n=89). Here, we show that the molecular subtypes of breast cancer differ in the expression profiles of AR and AR-associated microRNAs. In addition, the expression of AR and these microRNAs may depend on the expression of PR, ER, and HER2 receptors. Our results show that the possibility of using AR and microRNAs as markers depends on the tumor subtype: a decrease in AR expression may be the marker for the presence of lymph node metastases in patients with HER2-positive subtypes of breast cancer, and disturbance of miR-205, miR-185, and miR-21 expressions may be the marker in patients with a luminal B HER2-positive subtype. Cases with metastases in this type of breast cancer are characterized by a higher level of miR-205 and a lower level of miR-185 and miR-21 in tumor tissues compared to nonmetastatic cases. A decrease in the miR-185 level is also associated with lymph node metastasis in luminal B HER2-negative breast cancer. Thus, the expression levels of AR, miR-185, miR-205, and miR-21 can serve as markers to predict cancer spread to the lymph node in luminal B- and HER2-positive subtypes of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document